You are here

Primary tabs

InSitu Biologics

Updates

July 11
InSitu Biologics SEC Qualification Update

This is Jim Segermark, CEO of InSitu Biologics, Inc., with a quick update.

 

We continue to work with SEC to qualify our RegA+ Offering. You can now view the current version of the Offering Circular at www.insitubiologics.com or directly from the SEC website here.

 

When we are qualified to begin selling shares, you will get multiple emails, including one with specific instructions on how you can make your investment.  We will need approximately 24-36 hours after SEC qualification to begin receiving your investments.

 

Thank you for your patience.  We continue to make progress toward our Phase 1 Clinical Study, and I look forward to reporting on that to you in the future.

 

Regards,

James Segermark

President & CEO

InSitu Biologics, LLC

(651) 338-4801

www.insitubiologics.com

An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement, which only means that the company may make sales of the securities described by the offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement from the here.
You should read the offering circular before making any investment.

The offering materials may contain forward-looking statements and information relating to, among other things, Insitu Biologics, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify and constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.